Targeting Polθ’s Dual Domains to Guide Candidate Selection & Strategic Partnering

• See how Breakpoint Therapeutics is guiding candidate selection by comparing helicase vs. polymerase inhibition to inform domain targeting

• Presenting Breakpoint’s candidate molecule and second-generation compound with updated preclinical efficacy and safety data

• Contextualizing Breakpoint’s program within the broader Polθ landscape to highlight differentiation and partnering potential

Speakers:

Jon Hollick

Managing Director & Head of Research

Breakpoint Therapeutics